Dexpramipexole Enhances K

Elisabetta Coppi, Daniela Buonvicino, Giuseppe Ranieri, Federica Cherchi, Martina Venturini, Anna Maria Pugliese, Alberto Chiarugi

Open access · greenAbstract read

PubMed Publisher

In one paragraph

Article in Molecular neurobiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

0.3field-weighted citation impact, top 52% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

The FDA-approved compound, pramipexole and the clinical-stage investigational drug, dexpramipexole, reverse chronic allodynia from sciatic nerve damage in mice, and alter IL-1β and IL-10 expression from immune cell culture.Neuroscience letters · 2023
Article
Dexpramipexole Attenuates White Matter Injury to Facilitate Locomotion and Motor Coordination Recovery via Reducing Ferroptosis after Intracerebral Hemorrhage.Oxidative medicine and cellular longevity · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Elisabetta CoppiDepartment of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, Florence, Italy. elisabetta.coppi@unifi.it.ORCID http://orcid.org/0000-0003-4434-5919

Daniela BuonvicinoDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

Giuseppe RanieriDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

Federica CherchiDepartment of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.

Martina VenturiniDepartment of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.

Anna Maria PuglieseDepartment of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.

Alberto ChiarugiDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

University of Florence · IT

Funding

Fondazione Cassa di Risparmio di Firenze IG 2017 - ID. 204Fondazione Italiana Sclerosi Multipla 2014/R/6Fondazione Italiana Sclerosi Multipla 2019/R-Single/036Fondazione Umberto Veronesi FUV2020-3299

6 · The paper itself

Abstract

Dexpramipexole (DEX) has been described as the first-in-class F1Fo ATP synthase activator able to boost mitochondrial bioenergetics and provide neuroprotection in experimental models of ischemic brain injury. Although DEX failed in a phase III trial in patients with amyotrophic lateral sclerosis, it showed favorable safety and tolerability profiles. Recently, DEX emerged as a Nav1.8 Na

Indexed as

Action PotentialsAnimalsDopamine AntagonistsExcitatory Postsynaptic PotentialsHippocampusNeuronsPotassium ChannelsPramipexolePyramidal CellsRatsRats, WistarReceptors, DopamineSynaptic TransmissionDopamine AntagonistsPotassium ChannelsPramipexoleReceptors, DopamineHippocampal neuronsK+ channelsNeuronal excitabilityPopulation spikeSynaptic transmission

Identifiers

PMID33566318

DOI10.1007/s12035-021-02300-5

OpenAlexW3128524134

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.